Airway Basal Stem Cells for COPD: Lecheng’s Regenerative Option

Chronic Obstructive Pulmonary Disease (COPD) remains a leading cause of morbidity and mortality worldwide, characterized by progressive airflow limitation and irreversible destruction of lung parenchyma. Current pharmacologic therapies—bronchodilators, inhaled corticosteroids, and oxygen support—primarily alleviate symptoms but do not arrest the relentless decline in lung function. Against this backdrop, the emergence of airway basal stem cell (ABSC) therapy, now being implemented at Ruijin Lecheng Hospital (affiliated with Shanghai Jiao Tong University School of Medicine) within the Hainan Boao Lecheng International Medical Pilot Zone, has attracted considerable clinical interest. As a service coordinator based in Lecheng, I have been assisting patients in evaluating this novel approach. This article provides a factual, evidence-based overview of the technology, its clinical rationale, and the practicalities of accessing it.

Airway basal stem cells are a population of multipotent progenitor cells located in the pseudostratified epithelium of the conducting airways. Under physiological conditions, they are responsible for the routine renewal and repair of the airway epithelium following injury. In COPD, however, the chronic inflammatory environment—driven by cigarette smoke and other pollutants—exhausts this regenerative capacity, leading to squamous metaplasia, goblet cell hyperplasia, and ultimately, structural airway damage.

The therapy developed at Ruijin Lecheng Hospital involves harvesting autologous basal stem cells from the patient’s own large airways via bronchial brushing. These cells are then expanded ex vivo in a GMP-compliant laboratory, characterized for purity and potency, and transplanted back into the patient’s damaged airways through a bronchoscopic procedure. Because the cells are autologous, the risk of immune rejection is inherently low.

The therapeutic effect of ABSC transplantation is not solely attributable to direct replacement of lost epithelial cells. The mechanisms are multifaceted:

It is important to distinguish this approach from mesenchymal stromal cell (MSC) therapy. While MSCs primarily exert immunomodulatory effects and are often delivered systemically, ABSCs are tissue-resident stem cells delivered locally. Their primary function is structural repair of the epithelial layer—a more targeted and anatomically rational strategy for COPD.

The clinical development of ABSC therapy is rooted in foundational research conducted at the Shanghai Ruijin Hospital’s Respiratory Department, led by a team that has published extensively on the isolation and therapeutic application of these cells. While large-scale multicenter trials are ongoing, Phase I/II data reported in peer-reviewed respiratory journals (including studies published in Cell Research and European Respiratory Journal) have documented measurable improvements in several key parameters:

• Forced Expiratory Volume in 1 second (FEV1): Patients receiving ABSC transplantation have shown a statistically significant increase in FEV1 at 6- and 12-month follow-ups, representing an improvement in airflow that is rarely achieved with standard pharmacotherapy. In some cohorts, the mean increase in FEV1 has exceeded 100 ml—a threshold considered clinically meaningful.
• 6-Minute Walk Distance (6MWD): Objective measures of exercise capacity have improved, with patients walking substantially farther than pre-treatment baselines.
• Quality of Life (CAT and SGRQ scores): Patient-reported outcomes, including the COPD Assessment Test and St. George’s Respiratory Questionnaire, have indicated significant reductions in symptom burden and improvement in daily functioning.
• Reduced Exacerbation Rates: Preliminary data suggest a reduction in the frequency of acute exacerbations, which are the primary drivers of hospital admissions and disease progression.

Case reports from the Ruijin Lecheng program align with these trends. One patient with GOLD Stage III COPD, who was dependent on long-term oxygen therapy, demonstrated an increase in FEV1 from 1.12 L to 1.41 L at 12 months post-treatment, accompanied by a marked reduction in daily supplemental oxygen requirements. However, outcomes are not uniform; individual responses vary based on disease severity, baseline inflammatory status, and the extent of emphysematous destruction.

Eligibility for ABSC therapy is determined through a rigorous screening process at Ruijin Lecheng Hospital. The selection criteria are designed to identify patients most likely to derive clinical benefit while minimizing risks.

Inclusion criteria generally include:

• Confirmed diagnosis of COPD (FEV1/FVC < 0.7) with GOLD Stage II–IV.
• Age between 40 and 75 years.
• Demonstrated poor response to optimal medical therapy (e.g., triple inhaled therapy).
• Stable disease for at least 4 weeks prior to the procedure (no acute exacerbation).
• Willingness and ability to comply with the treatment protocol and follow-up schedule.

Exclusion criteria are comprehensive and include:

• Concurrent malignancy or active infectious diseases.
• Severe cardiovascular disease (unstable angina, uncontrolled arrhythmias).
• Significant other lung pathology (e.g., large bullae occupying > 1/3 of a lung, active tuberculosis, pulmonary fibrosis).
• Pregnancy or breastfeeding.
• Coagulopathy or contraindications to bronchoscopy.
• History of organ transplantation or long-term immunosuppressant use.

Candidates undergo a thorough pre-procedural workup, including high-resolution CT (HRCT) to assess the distribution of emphysema and airway wall thickness, pulmonary function testing, arterial blood gas analysis, and a comprehensive laboratory panel.

The clinical pathway for ABSC therapy at Ruijin Lecheng Hospital is clearly delineated and involves multiple stages:

1. Remote screening and consultation: Patients submit their complete medical records, including pulmonary function tests and imaging, for preliminary eligibility review.
2. On-site admission and bronchoscopic biopsy (harvesting): The patient undergoes a bronchoscopic procedure under sedation to collect airway epithelial cells. This is a minimally invasive day-case procedure.
3. Ex vivo cell expansion: The harvested basal stem cells are transported to a GMP facility for isolation, expansion, and quality control. This process typically takes 3–4 weeks. The final cell product undergoes rigorous sterility, viability, and purity testing.
4. Transplantation (re-infusion): The expanded cells are delivered back into the patient’s airways via a second bronchoscopy. The cells are selectively delivered to the most damaged but still viable segments of the airways.
5. Post-procedural monitoring and follow-up: Patients are observed for 24–48 hours post-transplantation. Structured follow-ups occur at 1, 3, 6, and 12 months, including repeat pulmonary function tests and quality-of-life assessments.

The total duration from harvest to re-infusion is typically 4–6 weeks, making this a feasible option for patients traveling from outside Hainan.

As a service provider, I recognize that financial considerations are paramount. The current estimated cost for the complete ABSC therapy package at Ruijin Lecheng Hospital is approximately ¥400,000 to ¥500,000 RMB. This comprehensive fee typically covers:

• Initial screening and diagnostic evaluations.
• Two bronchoscopic procedures (harvesting and transplantation).
• GMP-grade cell isolation, culture, and quality assurance.
• Hospitalization costs for the observation periods.
• Structured follow-up assessments for one year.

It is important to note that this estimate does not include travel expenses, accommodation, or ancillary medications (such as antibiotics or mucolytics) not directly part of the cell therapy protocol. Patients are advised to request a detailed, personalized cost breakdown during the initial consultation.

This program operates under the conditional approval framework of the Boao Lecheng Pilot Zone, which allows for the clinical application of advanced biomedical technologies that have demonstrated safety and efficacy in earlier-phase clinical trials. The manufacturing process for ABSCs is conducted under strict Good Manufacturing Practice (GMP) standards, with comprehensive sterility, mycoplasma, and endotoxin testing.

Regarding safety, the published literature and data from Ruijin’s clinical experience indicate that ABSC transplantation is generally well-tolerated. The most common adverse events are related to the bronchoscopic procedures themselves—transient sore throat, mild hemoptysis, or low-grade fever—and these typically resolve within 48 hours. To date, no cases of tumorigenesis, ectopic tissue formation, or severe immune reactions have been reported in the clinical cohort.